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Abstract
Purpose Diarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those 
targeting the ErbB family of receptors being associated with the highest rate of diarrhea.
Methods This paper reviews data on the incidence, timing, and duration of diarrhea associated with US Food and Drug 
Administration-approved ErbB family-targeted TKIs from the published literature, and sets forth recommendations for 
management.
Results In the absence of anti-diarrheal prophylaxis the incidence of any-grade diarrhea varies and typically occurs early 
during the course of treatment. Although it is difficult to determine if the incidence and severity of diarrhea is related to inhi-
bition of a particular kinase target because of the multi-targeted and overlapping activity of many agents, evidence suggests 
that second-generation TKIs with broader target profiles (i.e., afatinib, lapatinib, neratinib) result in a higher incidence of 
diarrhea compared with highly specific first- (erlotinib, gefitinib) or third- (osimertinib) generation agents. The mechanisms 
responsible for TKI-associated diarrhea are not fully understood and are likely multi-factorial, involving dysregulated ion 
transport, inflammation, and mucosal injury. Management strategies have been developed—and continue to be refined—to 
prevent and reduce the severity and duration of TKI-associated diarrhea. For agents associated with more significant symp-
toms, anti-diarrheal prophylaxis reduces the incidence and severity of diarrhea, and ongoing studies are evaluating specific 
strategies to further reduce incidence and duration of TKI-associated diarrhea.
Conclusions Continued investigations into risk factors and pharmacogenomic markers for diarrhea may further improve 
management of this common toxicity.
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Abbreviations
EGF  Epidermal growth factor
EGFR  Epidermal growth factor receptor
FDA  US Food and Drug Administration
HER  Human epidermal growth factor receptor
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Introduction
Currently, 37 different tyrosine kinase inhibitors (TKIs) are 
approved by the US Food and Drug Administration (FDA) 
for the treatment of various cancers (Table 1) [1, 2]. These 
orally administered targeted agents improve patient out-
comes in a variety of settings; however, TKIs have a unique 
adverse event profile including gastrointestinal and cutane-
ous side effects that must be recognized and managed appro-
priately [3, 4].
Diarrhea is a common adverse event associated with 
TKIs. The incidence of all-grade diarrhea in the absence of 
anti-diarrheal prophylaxis varies from 18 to 95% depend-
ing on the agent [5–12]. Diarrhea associated with TKIs can 
be severe and, if not properly managed, can lead to severe 
dehydration, dose reductions, and treatment interruptions or 
discontinuations. It is difficult to determine if the incidence 
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and severity of diarrhea is related to inhibition of a particular 
kinase target because of the multi-targeted and overlapping 
activity of many agents [13]. TKIs associated with the high-
est rate of diarrhea are those targeting the ErbB family of 
receptors (ErbB1 [HER1, EGFR1], ErbB2 [HER2], ErbB3 
[HER3], ErbB4 [HER4]), Bcr-Abl, phosphatidylinositol 
3-kinase (PI3K) delta, and vascular endothelial growth fac-
tor. In this review, we will focus on the ErbB-family TKIs, 
some of which target multiple members of the ErbB fam-
ily, but generally do not have target receptors beyond the 
ErbB family. Evidence suggests that second-generation 
agents, including afatinib, lapatinib, and neratinib, which 
have broader inhibitory profiles, result in a greater incidence 
of both all-grade and severe diarrhea compared with first-
generation agents such as erlotinib and gefitinib that are 
highly specific to epidermal growth factor receptor (EGFR). 
For example, the incidence of all-grade diarrhea reported in 
phase 3 clinical trials of erlotinib, a selective EGFR TKI, 
was 18–55%, and grade ≥ 3 diarrhea was reported in 3–6% 
of patients [14, 15]. In contrast, the incidence of all-grade 
diarrhea associated with afatinib, an ErbB-family TKI that 
blocks signaling from EGFR, human epidermal growth fac-
tor receptor 2 (HER2), and human epidermal growth factor 
receptor 4 (HER4), was 75–95%, with grade ≥ 3 diarrhea in 
10–14% of patients [5, 16, 17].
Signaling by the ErbB family of receptors plays a criti-
cal role in normal physiological functioning of cells; these 
receptors are expressed in a variety of epithelial, mesen-
chymal, and neuronal tissues and initiate a complex signal-
ing cascade, which regulates proliferation, differentiation, 
migration, and apoptosis [18]. Overexpression, activating 
mutations, and autocrine stimulation of ErbB-family recep-
tors—particularly EGFR and HER2—can lead to uncon-
trolled cell division via activation of multiple downstream 
signaling pathways [19–21], which is particularly com-
mon in breast and lung cancers. For example, up to 15% of 
Caucasian patients and 20–40% of Asian patients with non-
small cell lung cancer (NSCLC) have an activating EGFR 
mutation [22, 23]. HER2-positive breast cancers represent 
approximately 20% of all breast cancers and tend to be more 
aggressive than HER2-negative breast cancers [24]. Inhib-
iting EGFR and HER2 with receptor-targeted TKIs is an 
important therapeutic approach in these cancers. Currently, 
there are 6 approved TKIs that primarily target the ErbB 
family; some agents inhibit multiple members of the ErbB 
receptor family with varying levels of target specificity and 
activity (Table 2).
This review focuses on the incidence and management 
of diarrhea associated with the following 6 FDA-approved 
TKIs that target the ErbB-family receptors EGFR and 
HER2 (as of 31 August 2018): gefitinib, erlotinib, lapatinib, 
afatinib, neratinib, and osimertinib. Future considerations 
for optimizing the management of TKI-associated diarrhea 
based on current knowledge about the pathophysiology of 
diarrhea will also be discussed.
Literature search criteria and methods
Databases searched included Medline (last searched: March 
6, 2018); American Society of Clinical Oncology abstracts 
(2011–2017); European Society for Medical Oncology 
abstracts (2012–2016); San Antonio Breast Cancer Sympo-
sium abstracts (2014–2017); International Association for 
Table 1  FDA-approved TKIs [1, 2]
Abemaciclib Dabrafenib Nilotinib
Acalabrutinib Dasatinib Osimertinib
Afatinib Encorafenib Palbociclib
Alectinib Erlotinib Pazopanib
Axitinib Gefitinib Ponatinib
Binimetinib Ibrutinib Regorafenib
Bosutinib Idelalisib Ribociclib
Brigatinib Imatinib Sorafenib
Cabozantinib Lapatinib Sunitinib
Ceritinib Lenvatinib Trametinib
Cobimetinib Midostaurin Vandetanib
Copanlisib Neratinib Vemurafenib
Crizotinib
Table 2  Inhibitory profiles of FDA-approved ErbB family-targeted 
TKIs approved for BC and  NSCLCa [25, 26]
BC breast cancer, IC50 drug concentration causing 50% inhibition 
of the desired activity in in vitro EGFR kinase assays, EGFR epi-
dermal growth factor receptor, HER2 human epidermal growth fac-
tor receptor 2, HER4 human epidermal growth factor receptor 4, NR 
not reported, NSCLC non-small cell lung cancer, TKI tyrosine kinase 
inhibitors, WT wild type
a The measurement of  IC50 values is dependent on the assay; direct, 
cross-assay comparisons should be interpreted carefully
Agent Target(s) IC50, nM
Gefitinib EGFR 0.5–33
Erlotinib EGFR 0.6–0.8
Lapatinib EGFR 0.3–17
HER2 6–25
Afatinib EGFR 0.5
HER2 14
HER4 1
Neratinib EGFR 92
HER2 59
HER4 NR
Osimertinib WT EGFR 184
T790M EGFR 1
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the Study of Lung Cancer World Conference on Lung Can-
cer abstracts (2013–2016); clinicaltrials.gov; FDA oncol-
ogy approvals. Search terms were “diarrhea” AND “target 
therapy” [substance name].
Definition and differential diagnosis
The National Cancer Institute Common Toxicity Criteria for 
Adverse Events (NCI-CTCAE) provides standard grading 
for the severity of diarrhea, based primarily on the increase 
in the number of stools per day compared with baseline 
(Table 3) [27]. In clinical practice, these criteria, combined 
with patient assessment, laboratory data, and information 
obtained from symptom diaries about other physical symp-
toms such as fever, chills, and nausea, provide insight into 
the etiology and severity of the diarrhea, all of which are 
required for optimal patient management.
Based on the NCI-CTCAE grade and the presence or 
absence of additional symptoms, treatment-related diar-
rhea may be categorized as uncomplicated or complicated. 
Uncomplicated diarrhea is defined as grade 1 or 2 diarrhea 
without complicating signs or symptoms, including moder-
ate to severe cramping, nausea, vomiting, decreased per-
formance status, fever, sepsis, neutropenia, bleeding, and 
dehydration [28]. Mild to moderate (grade 1 or 2) diarrhea 
in the presence of at least 1 complicating factor, or diarrhea 
that is grade ≥ 3 is considered complicated [28].
When a patient experiences diarrhea during treatment, 
the first step is to rule out alternative causes [28]. The type 
of diarrhea is also important for proper management and 
control. Osmotic diarrhea is caused primarily by use of laxa-
tives or inefficient digestion of certain food substances. In 
this case, stool output is proportional to the intake of the 
unabsorbable substrate and is usually not severe; normal 
stool output returns with discontinuation of causative agent 
or food. In secretory diarrhea, the type of diarrhea that com-
monly occurs in patients taking TKIs, the ion transport pro-
cesses of the epithelial cells of the gastrointestinal tract are 
in a state of active secretion. Common causes of acute-onset 
secretory diarrhea (in a healthy individual not taking TKIs) 
are bacterial and viral infections of the gut. This should, of 
course, be ruled out in patients receiving targeted therapies, 
although infections are not common in this setting.
Pathophysiology
Understanding the underlying pathologic cause of TKI-
associated diarrhea is important for determining appropriate 
prophylactic and/or treatment regimens, as well as devel-
oping new therapeutic strategies to reduce incidence and 
severity. However, the exact mechanism(s) responsible for 
TKI-induced diarrhea still need to be fully elucidated, and 
may be multi-factorial in nature [6, 29].
EGFR and, to a much lesser extent, HER2 are expressed 
on healthy cells throughout the body including in the gas-
trointestinal tract [30]. EGFR is expressed at high levels in 
the basolateral membranes of epithelial cells and is critical 
for maintaining normal gut function through the regulation 
of ion transport, including the negative regulation of intes-
tinal epithelial chloride secretion, which regulates the pas-
sive movement of water through the gastrointestinal lumen 
[31, 32]. Pre-clinical studies suggest that epidermal growth 
factor (EGF) decreases chloride secretion in T84 human 
colonic intestinal epithelial cells via a signaling cascade 
that involves protein kinase C and phosphatidylinositol 
3-kinase [33]. Dysregulation of intestinal ion transport sys-
tems (e.g., through EGFR inhibition) can increase chloride 
secretion and lead to secretory diarrhea [32], suggesting a 
possible mechanism for EGFR TKI-associated secretory 
diarrhea. There is also pre-clinical evidence suggesting a 
role for HER2 in the inhibitory effect of EGF on epithelial 
chloride secretion through the formation of EGFR/HER2 
heterodimers [34]. Inhibition of EGFR homodimer signal-
ing vs EGFR/HER2 heterodimer signaling may explain the 
observed differences in the gastrointestinal effects of EGFR- 
and HER2-targeted agents; however, direct evidence of this 
effect in the gastrointestinal tract is lacking [35]. Neverthe-
less, the proposed mechanism involving the dysregulation of 
ion transport systems does provide researchers with a novel 
Table 3  Severity of diarrhea by grade according to the NCI CTC for Adverse Events (NCI-CTCAE v4) [27]
ADL activities of daily living, AE adverse event, CTC Common Toxicity Criteria, NCI National Cancer Institute
Grade Description
1 (Mild) Increase of < 4 stools per day over baseline; mild increase in ostomy output compared to baseline
2 (Moderate) Increase of 4 to 6 stools per day over baseline; moderate increase in ostomy output compared to baseline
3 (Severe) Increase of ≥ 7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in 
ostomy output compared to baseline; limiting self-care ADL
4 (Life-threatening) Life-threatening consequences; urgent intervention indicated
5 (Death) Death
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target for further development of management strategies for 
TKI-associated diarrhea (see discussion later in this article).
A number of other elegant pre-clinical models have been 
developed to further investigate the mechanism(s) respon-
sible for TKI-associated diarrhea. An animal model of 
lapatinib-induced diarrhea that closely mimicked clinical 
symptoms did not support the hypothesis that disruption of 
chloride secretion contributes to lapatinib-induced diarrhea; 
lapatinib had no significant effect on serum chloride levels. 
In addition, there was no evidence of macroscopic or micro-
scopic tissue injury within the jejunum or colon, suggest-
ing that lapatinib alone does not cause epithelial damage. In 
contrast, combined treatment with paclitaxel and lapatinib 
in a rat model caused an increase in the incidence of severe 
diarrhea and weight loss compared with either agent alone, 
suggestive of intestinal tissue injury [36].
In contrast to the results reported for lapatinib [36], 
findings from models using other TKIs demonstrated TKI-
induced direct mucosal damage apparently leading to diar-
rhea [37]. Mice that received a 10-day treatment course 
of gefitinib demonstrated significant atrophy of the small-
intestinal wall, which resulted in a decreased absorptive 
surface area [38]. Similarly, intestinal mucosal damage was 
greater in mice treated with increasing doses of erlotinib 
over a 10-day period [39]. Finally, a rat model of neratinib-
induced diarrhea suggested that inflammation may also 
contribute to the pathogenesis of diarrhea. In this model, 
neratinib increased histological damage in the distal ileum 
as well as production of pro-inflammatory cytokines, such 
as interferon-ɣ, in the ileum [40].
Treatment with budesonide, a corticosteroid with low 
oral bioavailability, decreased the number of days that 
the rats had diarrhea and reduced histopathological injury 
induced by neratinib [40]. In addition, budesonide reduced 
the activity of the inflammatory marker, myeloperoxidase, 
and increased levels of interleukin-4, an anti-inflammatory 
cytokine, while decreasing levels of interferon-ɣ. The effects 
of budesonide and colesevelam, a bile acid sequestrant, are 
currently being investigated in an ongoing Australian rat 
model study of neratinib-induced diarrhea.
Multiple other mechanisms—or a combination of mecha-
nisms—have also been proposed as potential causes of TKI-
induced diarrhea, including changes in gut motility, dam-
age in the colonic crypts, and altered interstitial microflora 
[6]. Unfortunately, inter-species differences between model 
systems (and individuals), in conjunction with variability 
in the target profile of individual TKIs, make it difficult to 
pinpoint the precise mechanism(s) responsible for the asso-
ciated diarrhea.
Clinical experience
Diarrhea, a common side effect of many cancer treatments, 
including chemotherapeutic agents, targeted therapies, and 
pelvic radiotherapy, is one of the most common adverse 
events reported during treatment with a TKI, and can be 
dose-limiting for TKIs that block EGFR signaling [41]. 
Effective clinical management of TKI-associated diarrhea 
requires a clear understanding of incidence, severity, onset, 
and duration. The incidence of all-grade diarrhea reported 
for gefitinib, erlotinib, afatinib, and osimertinib in NSCLC 
and lapatinib and neratinib in breast cancer varies from 18 to 
95% depending on the agent (Table 4) [5–12]. Among TKIs 
targeting the ErbB family of receptors, it appears that the 
incidence and severity of diarrhea increase with the increas-
ing breadth of targets. Newer, second-generation TKIs 
were developed with broader target profiles in an attempt to 
Table 4  FDA-approved 
oncology ErbB family-targeted 
TKIs approved for BC and 
NSCLC by frequency of 
associated diarrhea
BC breast cancer, EGFR epidermal growth factor receptor, HER2 + human epidermal growth factor recep-
tor 2-positive, NR not reported, NSCLC non-small cell lung cancer, TKI tyrosine kinase inhibitors
a From phase 3 clinical trials
b In 50–62% of patients and 71% of patients, respectively, across clinical trials
c Without loperamide prophylaxis; 1 patient experienced grade 4 diarrhea
d For grade 3 diarrhea. Duration represents cumulative duration over the course of a year
e In almost half of the patients with diarrhea
Agent Year approved Cancer Diarrhea, %a Median time, days
All-grade Grade 3/4 Onset Duration
Afatinib [5, 6] 2013 NSCLC 87–95 5–17 7–14b NR
Neratinib [7, 8] 2017 HER2 + BC 95 40c 2 5d
Lapatinib [9] 2007 BC 65 14 ~ 6e 4–5
Osimertinib [11] 2015 NSCLC 41 1 NR NR
Gefitinib [12] 2003 NSCLC 27–69 1–25 NR NR
Erlotinib [10] 2004 NSCLC; pan-
creatic cancer
18–68 1–12 12–32 NR
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improve the duration of response and overcome resistance 
to acquired mutations. However, the benefits of these agents 
come at a cost, with the potential for a higher incidence 
of adverse events compared with more selective reversible 
TKIs. Diarrhea was reported in 87–95% of patients receiving 
afatinib and neratinib, both of which are second-generation 
irreversible TKIs [16, 29, 42], compared with 18–69% of 
patients receiving erlotinib and gefitinib [9, 12]. The sever-
ity of diarrhea also varies with target profile, with grade 
≥ 3 diarrhea reported in up to 25% of patients treated with 
more focally targeted first-generation TKIs and up to 40% 
of patients treated with broadly targeted second-generation 
TKIs.
TKI-associated diarrhea typically occurs early during a 
course of treatment. For example, in studies without anti-
diarrheal prophylaxis, diarrhea associated with afatinib typi-
cally occurs in 50–62% of patients within the first 7 days 
of therapy and in 71% of patients by 14 days after initiat-
ing treatment [6]. Similarly, in the phase 3 ExteNET trial 
(which did not include anti-diarrheal prophylaxis), 40% of 
patients taking neratinib experienced grade 3 diarrhea after a 
median of 8 days (interquartile range 4–33), lasting a median 
of 5 days (interquartile range 2–9) per patient, with a median 
of two grade ≥ 3 diarrhea events per patient over the course 
of 1 year of treatment [42].
In clinical trials, TKI-associated diarrhea is a leading 
cause of dose reductions and treatment discontinuations. In 
the pivotal trial evaluating afatinib for metastatic NSCLC, 
diarrhea resulted in dose reductions and treatment discon-
tinuations in 20% and 1.3% of patients in the afatinib arm, 
respectively [16]. Similarly, in the ExteNET trial, 26% of 
patients taking neratinib for 1 year without anti-diarrheal 
prophylaxis required dose reductions due to diarrhea and 
17% discontinued treatment. Both dose reductions and dis-
continuations occurred early (median of 20 days after treat-
ment initiation, interquartile range 9–56 days) [42]. Impor-
tantly, diarrhea associated with neratinib resolved quickly 
when treatment was held and was rarely associated with 
serious consequences (e.g., renal insufficiency) [43].
The safety profile is different for TKIs that specifically 
inhibit mutant targets and have a low affinity for wild-type 
receptors (e.g., osimertinib, a third-generation TKI that 
potently inhibits T790M EGFR but has a low affinity for 
wild-type EGFR). These agents are effective in patients 
whose tumors have acquired resistance to earlier-generation, 
more broadly specific TKIs and may reduce the adverse 
effects of inhibiting wild-type receptors and/or off-target 
effects in normal tissue. The reported incidence of all-grade 
and grade ≥ 3 diarrhea in patients treated with osimertinib 
was 41% and 1%, respectively, in the pivotal trial in patients 
with NSCLC [44]. Osimertinib-associated diarrhea may be 
due to low-level inhibition of wild-type EGFR [45] and/or 
non-EGFR related mechanisms that contribute to diarrhea, 
including direct mucosal damage, resulting in decreased 
absorption of water [37]. This hypothesis is consistent with 
the increased incidence of diarrhea observed with escalating 
doses of osimertinib in the phase 1 clinical trial [46]. Full 
investigations into third-generation agents are underway; 
however, toxicity is likely to vary by agent and target.
In summary, although diarrhea is a common side effect 
of all TKIs, data suggest that second-generation inhibitors 
are associated with the highest incidence of diarrhea, likely 
due to broader and off-target effects compared with first-
generation agents.
Management strategies
Numerous consensus guidelines and clinical recommenda-
tions have been published on the management of cancer 
treatment-induced diarrhea [47–50] and, recently, agent-
specific TKI-induced diarrhea [6, 29, 51, 52]. Diarrhea 
management recommendations are also included in the 
US prescribing information for these agents (Table 5) [5, 
7, 9–12]. Cancer treatment-induced diarrhea management 
recommendations and those for TKI-associated diarrhea are 
similar, with management based on severity and associated 
complications [48]. For example, most cases of uncompli-
cated grade 1 or 2 diarrhea can be managed effectively with 
self-administered anti-diarrheal agents such as loperamide, 
diphenoxylate/atropine, or racecadotril. Loperamide acts as 
an agonist on opioid receptors in the gastrointestinal tract, 
decreasing gut motility and inhibiting ion transport, but is 
minimally absorbed and thus has limited central nervous 
system effects [49, 53]. Racecadotril is an enkephalinase 
inhibitor with proven efficacy in models of hypersecretory 
diarrhea, but it does not enter the brain after oral administra-
tion and therefore has no central nervous system effects [54, 
55]. In contrast, patients with grade ≥ 3 and/or medically 
complicated diarrhea require more aggressive management, 
including treatment interruptions and re-initiation of treat-
ment at a reduced dose, in addition to anti-diarrheal thera-
pies. Medically complicated diarrhea may include moderate 
to severe cramping, grade ≥ 2 nausea/vomiting, decreased 
performance status, fever, sepsis, neutropenia, frank bleed-
ing, and dehydration [48], each of which needs to be evalu-
ated and treated. The early identification and proactive 
management of TKI-associated diarrhea may minimize the 
occurrence of high-grade events and further complications 
that lead to treatment discontinuations or hospitalizations.
Anti‑diarrheal prophylaxis
Although anti-diarrheal prophylaxis is not recommended 
for all TKIs before treatment initiation, prophylaxis has 
demonstrated success at reducing the incidence, severity, 
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and duration of diarrhea for agents with high upfront risk 
and continues to be investigated. The phase 3 ExteNET 
trial, evaluating 1 year of neratinib as extended adjuvant 
therapy in HER2 + breast cancer, did not mandate the use 
of anti-diarrheal prophylaxis, instead recommending treat-
ment with anti-diarrheal agents and/or dose modifications 
after symptom onset. Even though most occurrences of 
diarrhea were self-limiting (resolving quickly after drug 
hold), grade 3 diarrhea occurred in 40% of patients and 
17% of patients discontinued neratinib due to gastroin-
testinal adverse events. In patients with metastatic breast 
cancer or NSCLC, loperamide administered during the 
first month of neratinib treatment (with the first dose and 
continued through the first cycle of treatment) effectively 
reduced the rates of grade 3 diarrhea (0–17% across stud-
ies) [56–58]. As a result, anti-diarrheal prophylaxis with 
loperamide from the first dose through two cycles of treat-
ment, along with patient education, is the recommended 
approach for patients receiving neratinib as extended adju-
vant therapy [7]. The effectiveness of this approach, as 
well as other anti-diarrheal agents, continues to be inves-
tigated in this setting.
An international, open-label, sequential-cohort, phase 2 
study (CONTROL) in HER2 + breast cancer patients receiv-
ing extended adjuvant neratinib therapy [59–61] is currently 
investigating the effects of several prophylactic strategies in 
reducing neratinib-associated diarrhea. The study cohorts 
include the following: mandatory loperamide prophylaxis 
(actual n = 137); loperamide + budesonide (actual n = 64); 
loperamide + the bile acid sequestrant colestipol (actual 
n = 136); colestipol + prn loperamide (actual n = 104); or a 
dose-escalation strategy (target n = 64, just starting to enroll) 
on neratinib-associated diarrhea [60, 61] (Table 6) [59, 62, 
63].
Interim data demonstrated that loperamide prophylaxis 
modestly reduced the incidence of grade ≥ 3 neratinib-asso-
ciated diarrhea compared with that reported in the phase 3 
ExteNET trial without anti-diarrheal prophylaxis (30.7% vs 
39.9%, respectively). Adding budesonide or colestipol fur-
ther reduced the incidence of grade ≥ 3 diarrhea (26.6% and 
Table 5  Diarrhea management recommendations available in the US prescribing information for ErbB family-targeted TKIs approved for BC 
and NSCLC
Detailed recommendations can be found in the prescribing information for each agent
BC breast cancer, NSCLC non-small cell lung cancer, TKI tyrosine kinase inhibitors
a Management strategies include withholding treatment for severe (grade 3/4) or persistent (lasting up to 14 days) diarrhea, and resuming treat-
ment (potentially at a lower starting dose) when diarrhea is grade ≤1
Agent Anti-diarrheal treatment 
(e.g., loperamide)
Dose reduc-
tions
Dose 
 interruptionsa
Anti-diarrheal 
prophylaxis
Patient education/
information
Supportive care
Gefitinib [12] ✓
Erlotinib [10] ✓ ✓ ✓ ✓
Lapatinib [9] ✓ ✓ ✓ ✓ ✓
Afatinib [5] ✓ ✓ ✓ ✓
Neratinib [7] ✓ ✓ ✓ ✓ ✓ ✓
Osimertinib [11] ✓
Table 6  Ongoing clinical trials of EGFR/HER2-targeted TKI-associated diarrhea
BC breast cancer, EGFR epidermal growth factor receptor, HER2 + human epidermal growth factor receptor 2-positive, mBC metastatic breast 
cancer, TKI tyrosine kinase inhibitors
Agent Phase Estimated 
enrollment
Design Title
Lapatinib [62] 2 140 Randomized, parallel, open label A randomized, multicenter, open-label, phase 2 study of prophylactic 
octreotide to prevent or reduce the frequency and severity of diarrhea in 
subjects receiving lapatinib with capecitabine for the treatment of mBC 
(NCT02294786)
Neratinib [63] 2 23 Single-arm, open label An open-label study to characterize the incidence and severity of diarrhea 
in patients with early-stage HER2 + BC treated with adjuvant trastu-
zumab and neratinib followed by neratinib monotherapy, and intensive 
anti-diarrheal prophylaxis (NCT03094052)
Neratinib [59] 2 240 Non-randomized, sequential 
cohort, open label
An open-label study to characterize the incidence and severity of diarrhea 
in patients with early-stage HER2 + BC treated with neratinib and inten-
sive loperamide prophylaxis (CONTROL) (NCT02400476)
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10.8%, respectively) [60, 61], suggesting that the etiology 
of neratinib-associated diarrhea may involve inflammation 
and/or bile acid malabsorption. Compared with the ExteNET 
trial, prophylaxis with loperamide alone also reduced the 
median cumulative duration of diarrhea grade ≥ 2 (4 vs 10 
days) and grade ≥ 3 (3 vs 5 days) and reduced the median 
number of diarrhea episodes (any grade) per patient (2 vs 8 
episodes). Of note, no grade 4 diarrhea events have occurred. 
These data suggest that effective anti-diarrheal prophylaxis 
may help improve the tolerability of neratinib, and ongoing 
cohorts are exploring colestipol alone or a neratinib dose-
escalation strategy.
Investigations are underway to develop pharmacologic 
management approaches targeting chloride channels, which 
may be an important mechanism associated with EGFR 
inhibitors. Crofelemer, an established anti-diarrheal agent 
for other conditions, inhibits chloride channels in the mem-
brane of epithelial cells [64] and has been investigated in 
patients with breast cancer receiving targeted therapies in 
combination with chemotherapy [65, 66]. An ongoing study 
is investigating anti-diarrheal prophylaxis with crofelemer 
in HER2-positive patients treated with adjuvant trastuzumab 
and neratinib followed by neratinib monotherapy (Table 5) 
[63].
Based on the incidence and severity of lapatinib-associ-
ated diarrhea, studies continue to assess the clinical utility 
of anti-diarrheal prophylaxis. A small retrospective analysis 
of 44 patients treated with lapatinib suggested that anti-diar-
rheal prophylaxis may be an effective strategy for patients to 
achieve therapy goals without interruptions or dose adjust-
ments [67]. An ongoing, randomized, phase 2 study with an 
estimated enrollment of 140 patients will assess the effect 
of prophylactic octreotide, a somatostatin analog and estab-
lished anti-diarrheal agent for cancer treatment-induced 
diarrhea, to prevent or reduce the frequency and severity of 
diarrhea in subjects receiving lapatinib in combination with 
capecitabine for the treatment of HER2 + metastatic breast 
cancer (Table 5) [62].
Further research is needed to reduce constipation asso-
ciated with prophylactic regimens and optimize tolerabil-
ity. For example, in the CONTROL trial, rates of grade 1/2 
constipation were 42.3%/14.6% in patients receiving lopera-
mide prophylaxis alone, 62.5%/12.5% with loperamide plus 
budesonide, and 53.3%/9.2% with loperamide plus colestipol 
[61]. An ongoing area of investigation in the CONTROL 
trial is whether anti-diarrheal prophylaxis will have a signifi-
cant impact on health-related quality of life (HRQoL) [59].
Monitoring
Clear communication between patients and physicians is 
critical to ensure accurate reporting and characterization of 
symptoms, exclude other potential causes, and to initiate 
therapy adjustments as needed. Close patient monitoring 
is critical for management of diarrhea during the first few 
weeks of therapy because diarrhea generally occurs within 
the first week for most TKIs (Table 3) [27]. Patients should 
be educated that diarrhea is a common side effect of TKIs 
and about the potential consequences of diarrhea, including 
dehydration, electrolyte imbalances, and renal insufficiency. 
Patients should be instructed on the use of anti-diarrheal 
treatment regimens either as prophylaxis or in case of mild 
to moderate diarrhea per treatment guidelines, and to moni-
tor the frequency of bowel movements. In addition, patients 
should be advised to inform their healthcare provider imme-
diately if diarrhea develops (i.e., more than 2–3 episodes per 
day), for severe or persistent diarrhea, or if diarrhea is asso-
ciated with weakness, dizziness, or fever. In clinical practice, 
patient diaries combined with proactive triage management 
and a thorough evaluation of treatment-emergent diarrhea 
help to ensure that appropriate management measures are 
taken.
Intervention
Proactive management of treatment-related diarrhea is rec-
ommended to reduce the incidence, duration, and severity. 
Loperamide is the mainstay for the pharmaceutical manage-
ment of uncomplicated mild to moderate diarrhea and is rec-
ommended in the prescribing information after the onset of 
diarrhea or as upfront prophylaxis [68]. In some cases, diar-
rhea persists despite administration of anti-diarrheal agents 
given prophylactically or at first onset of diarrhea. In this 
case, TKI treatment should be withheld until diarrhea has 
resolved to baseline or grade ≤1 and may be reinitiated per 
labeling. In cases of severe or persistent diarrhea, support-
ive care including the administration of oral or intravenous 
electrolytes and fluids, addition of alternative anti-diarrheal 
agents (e.g., diphenoxylate–atropine, octreotide, or tincture 
of opium), and diet modification are recommended [48]. 
Evaluation for infectious diarrhea or other causes should also 
be considered along with appropriate use of anti-infectives.
In all cases, patient education is critical to help patients 
identify the signs and symptoms of diarrhea and stress the 
need for urgent action (i.e., loperamide administration and 
contacting the patient’s physician for severe or persistent 
diarrhea).
Future directions
Novel pharmacologic approaches to TKI-associated diarrhea 
based on its pathophysiology will improve the quality of care 
and further optimize diarrhea management approaches for 
patients receiving these targeted therapies [59–61]. Research 
is needed to better understand risk factors for TKI-associated 
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diarrhea, with the goal of identifying those patients at 
greater risk and to manage diarrhea both proactively and 
emergently. A proof-of-principle study designed to quantify 
the risk factors for diarrhea in breast cancer patients treated 
with lapatinib identified risk factors including advanced age, 
starting treatment in the spring, a higher incidence of skin 
metastases, and grade 1 diarrhea in earlier treatment cycles 
[69]. Pharmacogenomic studies may help to further eluci-
date the pathophysiology of TKI-induced diarrhea and allow 
for the identification of vulnerable patients.
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